Clinical Trials

Stem Cell Therapeutics enters agreement to support phase 2a safety study of stroke therapy

Published in Drug Week, May 26th, 2006

Stem Cell Therapeutics Corp. (SCT) announced that it has entered into an agreement to support a phase 2a safety study examining the effects of NTx-265 in stroke patients. The regimen of drugs being tested in this study is referred to by SCT as NTx-265.

The phase 2a safety study has been reviewed and approved by both the U.S. Food and Drug Administration (FDA) and by the institutional review board (IRB) of the University of California, Irvine (UCI). The study will be conducted by Steven Cramer, a stroke specialist at UCI.

Patient screening for this open label study, expected to enroll approximately 12 subjects, is anticipated to begin in the near...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2006-05-26)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry